NCT03490292View on ClinicalTrials.gov

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

January 19, 2022

Study Completion Date

July 12, 2023

Conditions
Resectable Esophageal CancerGastroEsophageal Cancer
Interventions
COMBINATION_PRODUCT

Avelumab combined with Chemoradiation

Co-administration of avelumab with chemoradiation in pre-operative period.

DRUG

Carboplatin

Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

DRUG

Paclitaxel

Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]

RADIATION

Radiation

Radiation therapy \[23 fractions, M-F, estimated completion day 35\]

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT03490292 - Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | Biotech Hunter | Biotech Hunter